Saishu Yoshida

Saishu Yoshida

Auto-generated profile, based on publicly available information

Saishu Yoshida

Department of Biomolecular Science, Faculty of Science Toho University Chiba Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2020 in eLife
Verified
Journal Article
Open access
SYSaishu Yoshida
Saishu Yoshida
KAKatsuhiko Aoki
Katsuhiko Aoki
KFKen Fujiwara
Ken Fujiwara
TNTakashi Nakakura
Takashi Nakakura
AKAkira Kawamua
Akira Kawamua
KYKiyotsugu Yoshida
Kiyotsugu Yoshida
Mammalian Hedgehog (Hh) signaling plays key roles in embryogenesis and uniquely requires primary cilia. Functional analyses of several ciliogenesis-related genes led to the discovery of the developmental diseases known as ciliopathies. Hence, identification of mammalian factors that regulate ciliogenesis can provide insight into the molecular mechanisms of embryogenesis and ciliopathy. Here, we demonstrate that DYRK2 acts as a novel mammalian ciliogenesis-related protein kinase. Loss ofDyrk2in mice causes suppression of Hh signaling and results in skeletal abnormalities during in vivo embryogenesis. Deletion ofDyrk2induces abnormal ciliary morphology and trafficking of Hh pathway components. Mechanistically, transcriptome analyses demonstrate down-regulation ofAurkaand other disassembly genes followingDyrk2deletion. Taken together, the present study demonstrates for the first time that DYRK2 controls ciliogenesis and is necessary for Hh signaling during mammalian development.

5 July 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SYSaishu Yoshida
Saishu Yoshida
AKAkira Kawamua
Akira Kawamua
KAKatsuhiko Aoki
Katsuhiko Aoki
PWPattama Wiriyasermkul
Pattama Wiriyasermkul
SSShinya Sugimoto
Shinya Sugimoto
KYKiyotsugu Yoshida
Kiyotsugu Yoshida
Hedgehog (Hh) signaling, an evolutionarily conserved pathway, plays an essential role in development and tumorigenesis, making it a promising drug target. Multiple negative regulators are known to govern Hh signaling; however, how activated Smoothened (SMO) participates in the activation of downstream GLI2 and GLI3 remains unclear. Herein, we identified the ciliary kinase DYRK2 as a positive regulator of the GLI2 and GLI3 transcription factors for Hh signaling. Transcriptome and interactome analyses demonstrated that DYRK2 phosphorylates GLI2 and GLI3 on evolutionarily conserved serine residues at the ciliary base, in response to activation of the Hh pathway. This phosphorylation induces the dissociation of GLI2/GLI3 from suppressor, SUFU, and their translocation into the nucleus. Loss of Dyrk2 in mice causes skeletal malformation, but neural tube development remains normal. Notably, DYRK2-mediated phosphorylation orchestrates limb development by controlling cell proliferation. Taken together, the ciliary kinase DYRK2 governs the activation of Hh signaling through the regulation of two processes: phosphorylation of GLI2 and GLI3 downstream of SMO and cilia formation. Thus, our findings of a unique regulatory mechanism of Hh signaling expand understanding of the control of Hh-associated diseases.

27 April 2014 in Cell and tissue research
Verified
Journal Article
Closed access
PDF file
KHKotaro Horiguchi
Kotaro Horiguchi
KFKen Fujiwara
Ken Fujiwara
MHMasashi Higuchi
Masashi Higuchi
SYSaishu Yoshida
Saishu Yoshida
TTTakehiro Tsukada
Takehiro Tsukada
YKYukio Kato
Yukio Kato

31 August 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
KYKohji Yamada
Kohji Yamada
SMSaya Motohashi
Saya Motohashi
TOTsunekazu Oikawa
Tsunekazu Oikawa
NTNaoko Tago
Naoko Tago
RKRei Koizumi
Rei Koizumi
KYKiyotsugu Yoshida
Kiyotsugu Yoshida
Protein secretion in cancer cells defines tumor survival and progression by orchestrating the microenvironment. Studies suggest the occurrence of active secretion of cytosolic proteins in liver cancer and their involvement in tumorigenesis. Here, we investigated the identification of extended-synaptotagmin 1 (E-Syt1), an endoplasmic reticulum (ER)-bound protein, as a key mediator for cytosolic protein secretion at the ER–plasma membrane (PM) contact sites. Cytosolic proteins interacted with E-Syt1 on the ER, and then localized spatially inside SEC22B+vesicles of liver cancer cells. Consequently, SEC22B on the vesicle tethered to the PM via Q-SNAREs (SNAP23, SNX3, and SNX4) for their secretion. Furthermore, inhibiting the interaction of protein kinase Cδ (PKCδ), a liver cancer-specific secretory cytosolic protein, with E-Syt1 by a PKCδ antibody, decreased in both PKCδ secretion and tumorigenicity. Results reveal the role of ER–PM contact sites in cytosolic protein secretion and provide a basis for ER-targeting therapy for liver cancer.

22 January 2018 in Journal of Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
SYS. Yoshida
S. Yoshida
KFK. Fujiwara
K. Fujiwara
HNH. Nishihara
H. Nishihara
TKT. Kato
T. Kato
TYT. Yashiro
T. Yashiro
YKY. Kato
Y. Kato

12 May 2022 in Cancer Science
Verified
Journal Article
Open access
KYKohji Yamada
Kohji Yamada
RKRyusuke Kizawa
Ryusuke Kizawa
AYAyano Yoshida
Ayano Yoshida
RKRei Koizumi
Rei Koizumi
SMSaya Motohashi
Saya Motohashi
KYKiyotsugu Yoshida
Kiyotsugu Yoshida
Protein kinase C delta (PKCδ) is a multifunctional PKC family member and has been implicated in many types of cancers, including liver cancer. Recently, we have reported that PKCδ is secreted from liver cancer cells, and involved in cell proliferation and tumor growth. However, it remains unclear whether the extracellular PKCδ directly regulates cell surface growth factor receptors. Here, we identify epidermal growth factor receptor (EGFR) as a novel interacting protein of the cell surface PKCδ in liver cancer cells. Imaging studies showed that secreted PKCδ interacted with EGFR‐expressing cells in both autocrine and paracrine manners. Biochemical analysis revealed that PKCδ bound to the extracellular domain of EGFR. We further found that a part of the amino acid sequence on the C‐terminal region of PKCδ was similar to the putative EGFR binding site of EGF. In this regard, the point mutant of PKCδ in the binding site lacked the ability to bind to the extracellular domain of EGFR. Upon an extracellular PKCδ‐EGFR association, ERK1/2 activation, downstream of EGFR signaling, was apparently induced in liver cancer cells. This study indicates that extracellular PKCδ behaves as a growth factor and provides a molecular basis for extracellular PKCδ‐targeting therapy for liver cancer.